Last edition
News about "metabolic disorders "
Dr. Reddy's Delays Semaglutide Supplies Following API-Related Quality Issue
Dr. Reddy's Laboratories announces a temporary delay in commercial supplies of semaglutide after identifying an API-related quality issue affecting certain batches. The company is investigating the root cause and has confirmed that patient safety and existing global regulatory filings remain unaffected.
Metabolic Disorders | 09/07/2026 | By News Bureau
Emcure Slashes Price of Semaglutide-Based Weight Loss Drug Poviztra in India
Emcure reduces the price of its semaglutide-based drug Poviztra, aiming to make effective weight management treatment more accessible to patients across India.
Metabolic Disorders | 04/04/2026 | By News Bureau | 157
India’s drug regulator Central Drugs Standard Control Organisation warns pharmaceutical firms against direct or indirect promotion of prescription-only GLP-1 drugs for obesity, stressing strict compliance with the Drugs and Cosmetics Act, 1940.
Metabolic Disorders | 13/03/2026 | By News Bureau | 140
BioAge Labs Initiates Phase 1 Trial of Novel NLRP3 Inhibitor BGE-102 for Obesity Treatment
BioAge Labs, a clinical-stage biotechnology company based in Emeryville, California, has announced the initiation of a Phase 1 clinical study of BGE-102, an orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for the treatment of obesity.
Metabolic Disorders | 16/09/2025 | By Dineshwori | 262
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy